Navigation Links
Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
Date:9/1/2009

SAN DIEGO, Sept. 1 /PRNewswire/ -- Stemedica Cell Technologies, Inc., ("Stemedica"), a leader in adult stem cell research and manufacturing, announced today that it has been granted a license by the State of California's Food & Drug Branch to manufacture stem cells for human clinical trials. This Drug Manufacturing License recognizes Stemedica as being compliant with California law and the applicable provisions of the Code of Federal Regulations.

"This is an important development for Stemedica," said Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica. "With this license we become an even stronger worldwide leader within the stem cell industry. Our stem cells and stem cell-derived factors can now be purchased by pharmaceutical and biotech companies, research institutions and medical facilities conducting approved human clinical trials. As more and more organizations get involved with stem cell research and clinical trials, including drug discovery programs, Stemedica's ability to service their needs becomes a critical asset to the organization and to the industry."

"This stamp of approval positions Stemedica as one of only a few companies in the world capable of manufacturing and delivering its own unique multiple cell products and factors. The Company also has the ability to custom manufacture for select companies. These dynamic capabilities give us a significant point of advantage in the marketplace," said Roger Howe, PhD, Executive Chairman for Stemedica.

Stemedica has dedicated significant financial and human resources over the past four years in preparation for securing this license. The government's rigorous inspection and approval process has included: a comprehensive, in-depth audit of Stemedica's manufacturing process and procedures; examination of Stemedica's Quality Systems; interviews with facility management; and an onsite inspection of the facility.

"We're very proud of the hard work, dedication and professionalism of the team that has made this possible," stated Maynard Howe, PhD, Stemedica's Vice Chairman and Chief Executive Officer. "Their experience and expertise has been instrumental in assuring that our facility meets regulatory compliance requirements. With the approval and licensing process behind us we can now focus our efforts on manufacturing the highest quality stem cell products."

About Stemedica Cell Technologies

Stemedica Cell Technologies, Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company has currently filed a pre-IND request with the FDA in preparation of IND submissions for stroke and wound repair. Stemedica is headquartered in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com


'/>"/>
SOURCE Stemedica Cell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemedica Requests Pre-IND Meeting With FDA
2. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
3. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
5. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
6. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
7. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
8. Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
9. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
10. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
11. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... BERLIN , April 29, 2016 ... world-leading glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years ... pharmaceutical and biotechnology industries. His last role was at ... Member of the Executive Board. Previously Dr. Zurlo held ...
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... Mich. , April 28, 2016   ... . Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... has signed a definitive agreement to acquire Valley ... Specialty Pharmacy ("TNH"), a leading specialty pharmacy that ... Van Nuys, California . In 2015, TNH ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... The ... successful events, attracting medical professionals from around the globe who attended a week’s ... Opening Ceremonies Sunday, April 17 included the introduction of the 2016 ARRS Distinguished ...
(Date:4/28/2016)... Portland, Maine (PRWEB) , ... April 28, 2016 , ... ... of death and principal determinant of childhood mortality. This is particularly true in underdeveloped ... A lecture at the University of New England’s campus in Tangier, Morocco, will examine ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is being ... safety. The Healthy Ageing division can include everything from antioxidants, lipids, proteins, and ...
(Date:4/28/2016)... ... April 28, 2016 , ... The American Society for ... developers of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced ... platform is scheduled to launch in July 2016 and will be a combined ...
(Date:4/28/2016)... PA (PRWEB) , ... April 28, 2016 , ... ... Browne, M.D. has been named a Top Doc in Physical Medicine and Rehabilitation ... conjunction with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership ...
Breaking Medicine News(10 mins):